Sandbox:Sahar: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
Line 1: | Line 1: | ||
{| class="wikitable" | |||
! rowspan="2" style="background: #4479BA; width: 100px;" | {{fontcolor|#FFF|Amyloisosis subtype}} | |||
! colspan="3" style="background: #4479BA; width: 100px;" | {{fontcolor|#FFF|Clinical feature}} | |||
! rowspan="2" style="background: #4479BA; width: 100px;" | {{fontcolor|#FFF|Laboratory findings}} | |||
! rowspan="2" style="background: #4479BA; width: 100px;" | {{fontcolor|#FFF|}} | |||
|- | |||
! style="background: #4479BA; width: 100px;" | {{fontcolor|#FFF|}} | |||
! style="background: #4479BA; width: 100px;" | {{fontcolor|#FFF|}} | |||
! style="background: #4479BA; width: 100px;" | {{fontcolor|#FFF|}} | |||
|- | |||
|style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |Primary | |||
|_ | |||
|_ | |||
|✔ | |||
|[[Anemia]] | |||
| rowspan="4" |[[MRI]] is the best radiologic tool to differentiate between retroperitoneal masses. | |||
|- | |||
|style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |Secondary | |||
|✔ | |||
|_ | |||
|✔ | |||
|[[Leukocytosis]], positive inflammatory markers | |||
|- | |||
|style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |DRA (dialysis related amyloidosis) | |||
|✔ | |||
|✔ | |||
|✔ | |||
|positive [[tumor marker]] | |||
|- | |||
|style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |Senile systemic (cardiac) amyloidosis | |||
|_ | |||
|✔ | |||
|✔ | |||
|[[Diabetes mellitus|DM type II]], [[amylase]] and [[lipase]] levels may be slightly elevated | |||
|} | |||
{{familytree/start |summary=Sample 1}} | {{familytree/start |summary=Sample 1}} | ||
{{familytree | | | | | E04 | | | | |E04=[[Infection]]/[[Inflammation]]}} | {{familytree | | | | | E04 | | | | |E04=[[Infection]]/[[Inflammation]]}} |
Revision as of 05:19, 10 November 2019
Amyloisosis subtype | Clinical feature | Laboratory findings | |||
---|---|---|---|---|---|
Primary | _ | _ | ✔ | Anemia | MRI is the best radiologic tool to differentiate between retroperitoneal masses. |
Secondary | ✔ | _ | ✔ | Leukocytosis, positive inflammatory markers | |
DRA (dialysis related amyloidosis) | ✔ | ✔ | ✔ | positive tumor marker | |
Senile systemic (cardiac) amyloidosis | _ | ✔ | ✔ | DM type II, amylase and lipase levels may be slightly elevated |
Infection/Inflammation | |||||||||||||||||||||||
Increased production of IL-1/IL-6/TNF-α | |||||||||||||||||||||||
Upregulation of hepatic serum amyloid A production | |||||||||||||||||||||||
SAA production uptake by macrophages | |||||||||||||||||||||||
C-terminal cleavage of SAA | |||||||||||||||||||||||
β-sheet configuration of SAA | |||||||||||||||||||||||
Fibril deposition in extracellular space | |||||||||||||||||||||||
Binding of glycosaminoglycan, serum amyloid P, and lipid components | |||||||||||||||||||||||
Resistant to proteolysis | |||||||||||||||||||||||
The above algorithm is adopted from International Journal of Nephrology and Renovascular Disease[1] |
---|
Organ System Involvement | Differential Diagnosis | Causes | Clinical Features | Laboratory Findings | Gold Standard Test | Therapy |
---|---|---|---|---|---|---|
Nephrotic Syndrome and Renal Failure | Secondary (AA) Amyloidosis |
|
|
|
|
|
Primary (AL) Amyloidosis |
|
|
|
|||
Diabetic Nephropathy |
|
|
|
|||
Minimal Change Disease |
|
| ||||
Focal Segmental Glomerulosclerosis | ||||||
Fabry's Disease |
|
|
|
|
| |
Light Chain Deposition Disease |
|
|
| |||
Membranous Glomerulonephritis |
|
|
|
|
| |
Fibrillary-Immunotactoid Glomerulopathy |
|
|
|
|||
Organ System Involvement | Differential Diagnosis | Causes | Clinical Features | Laboratory Findings | Gold Standard Test | Therapy |
Polyneuropathy | POEMS syndrome (Demyelinating) |
|
|
|||
Metabolic Syndrome (Axonal pathology) |
|
|
|
|||
Vitamin Deficiencies (Axonal Pathology) |
|
|
|
| ||
Guillain-Barre Syndrome (Demyelinating) |
|
|
|
|||
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (Mixed axonal and demyelinatiing) |
|
|
|
|
||
Multifocal Motor Neuropathy |
|
|||||
Organ System Involvement | Differential Diagnosis | Causes | Features | Laboratory Findings | Gold Standard Test | Therapy |
Organomegaly (Hepatosplenomegaly and Lymphadenopathy) | Malaria |
|
|
| ||
Kala-azar |
|
|
|
|||
Infective Hepatitis |
|
|
||||
Chronic Myelogenous Leukemia (CML) |
|
|
||||
Lymphoma |
|
|
||||
Primary (AL) Amyloidosis |
|
|
|
| ||
Gaucher's Disease |
|
|
|
|
Example #1
The patient presented with S.O.B. one year after hysterectomy for a leiomyomatous uterus.
- ↑ Rumjon A, Coats T, Javaid MM (2012). "Review of eprodisate for the treatment of renal disease in AA amyloidosis". Int J Nephrol Renovasc Dis. 5: 37–43. doi:10.2147/IJNRD.S19165. PMC 3304340. PMID 22427728.